Consumption of a naturally occurring polyphenol, resveratrol, in particular through drinking moderate amounts of red wine, has been suggested to be beneficial to health. A plethora of in vitro studies published demonstrate various anti-inflammatory actions of resveratrol. The aim of this research was to determine whether any of these anti-inflammatory effects translate in vivo in a rodent model of LPS induced airway inflammation. Resveratrol reduced lung tissue neutrophilia to a similar magnitude as that achieved by treatment with budesonide. This was associated with a reduction in pro-inflammatory cytokines and prostanoid levels. Interestingly, the reduction did not appear to be due to an impact on NF-κB activation or the expression of the respective genes as suggested by various in vitro publications. These results suggest that resveratrol may possess anti-inflammatory properties via a novel mechanism. Elucidation of this mechanism may lead to potential new therapies for the treatment of chronic inflammation.
Considerable evidence demonstrates anti-inflammatory properties of resveratrol, including inhibition of reactive oxygen species in neutrophils (7), monocytes (8), and macrophages (9). Rotondo et al. (7) showed that resveratrol reduced elastase and β-glucuronidase secretion and β2 integrin MAC-1 expression on neutrophils. Other groups have published on the inhibitory effect of resveratrol on the expression of the adhesion molecules ICAM-1, VCAM-1 (Intercellular adhesion molecule-1, vascular cell adhesion molecule-1) (10), and E-selectin (11) on endothelial cells. Ferrero (12) also reported that resveratrol reduced granulocyte and monocyte adhesion to endothelial cells. The release of various cytokines from macrophages and lymphocytes, such as IL-6 (13, 14) , IFNγ, IL-2, TNF-α, and IL-12 (15) , has been shown to be inhibited by resveratrol. In stimulated macrophages the expression of iNOS and the release of nitric oxide are reduced by resveratrol (14, 16, 17) . A reduction of cyclooxygenase (COX)-1 (18) and COX-2 (19) expression and activity by resveratrol is also apparent. Others have shown an inhibition of MMP-9 (matrix metalloproteinase-9) expression by resveratrol (20, 21) . Resveratrol also has the ability to increase apoptosis by decreasing Bcl-2 expression (22) and increasing caspase substrate levels (23) and Bax expression (24) along with reducing cell proliferation (25, 26) . A common link between the inhibitory effects of resveratrol mentioned above could be its ability to inhibit factors involved in gene transcription like MAPK, c-JNK, AP-1, and NF-κB (27) . Indeed, recently the effect of resveratrol on NF-κB has been of particular interest. It has been suggested that resveratrol acts on NF-κB by the inhibition of Iκ-B kinase, which results in the prevention of translocation of NF-κB into the nucleus (28) or through its sirtuin-like activity, which deacetylates NF-κB (29, 30) .
Many of the inflammatory biomarkers reported to be impacted on by resveratrol in vitro are known to be implicated in LPS-induced airway inflammation, including NO; TNF-α; IL-1β; the IL-8/GROα equivalent in rats CINC 1, 2, and 3; P and L selectin; IL-6; and VCAM-1 (31) (32) (33) (34) (35) . This study aimed to determine the effect of resveratrol, in parallel with a glucocorticoid-positive control, on LPS-induced airway inflammation in the rat. Resveratrol has low oral bioavailability (36) ; hence it has been suggested that regular consumption of resveratrol, i.e., through frequently drinking moderate amounts of red wine, is necessary to achieve the beneficial effects on health. It is not know what length of time is necessary to orally consume resveratrol to achieve the possible anti-inflammatory affects. Hence, in this study, to avoid the need for chronic oral administration and associated subsequent pharmokinetic profiling, the compound was administered directly into the airways. This study focuses on the inflammation in the lung tissue because this allowed comparison between effects on NF-κB pathway activation, inflammatory gene and protein expression and cellular recruitment.
MATERIALS AND METHODS

Induction of airway inflammation and drug treatment
Male Wistar rats (230-250 g) were purchased from Harlan-Olac (Bicester, UK) and allowed to acclimatize for at least 5 days before use. Food and water were supplied ad libitum. UK Home Office guidelines for animal welfare based on the Animals (Scientific Procedures) Act 1986 were strictly observed.
Rats were dosed vehicle (0.5% methylcellulose and 0.2% tween 80 in saline, 1 ml/kg), micronized resveratrol (1, 3, 10, or 30 mg/kg; a kind gift from Royal Mount Pharma, Montreal, QC, Canada) or budesonide (0.3, 1, 3 and 10 mg/kg, from Sigma, Poole, UK) intratracheally under halothane (4% in oxygen for 4 min). After 90 min, the rats were exposed to aerosolized saline or LPS (0.3 mg/ml, E-Coli Serotype 0111:B4, from Sigma) for 30 min using an Ultra-Neb 99 (Sunrise Medical Ltd., Wollaston, UK). Each treatment group consisted of eight animals.
Quantification of airway cellular inflammation
Six hours after saline or LPS challenge, animals were euthanized with sodium pentobarbitone (200 mg/kg, i.p.). Inflammatory cell recruitment in the lung was assessed in accordance with a method outlined in Underwood et al. (37) . Briefly, after lavaging the airways with RPMI (1L/100 g body weight times two, pooled), the left lobe was removed and the vasculature was perfused with RPMI to remove any blood and then finely chopped. A 300 mg aliquot of the lung tissue went through an enzymatic digest to extract the white cells. The remaining lung was flash frozen in liquid nitrogen and stored at -80°C for analysis of cytokine protein and gene expression.
Total white blood cell counts in the lung samples were determined using an automated cell counter (Sysmex F-820, Sysmex UK Ltd., Linford Wood, Buckinghamshire, UK). Cytospins of these samples were prepared by centrifugation of 100 µl aliquots in a cytospin (Shandon, Runcorn, UK) at 700 rpm for 5 min, low acceleration at room temperature. Slides were fixed and stained on a Hema-tek 2000 (Ames Co., Elkhart, IN) with modified Wrights-Giemsa stain. Fourpart differential counts on 200 cells per slide were performed following standard morphological criteria and the percentage of eosinophils, lymphomononuclear cells, and neutrophils were determined.
Neutrophil myeloperoxidase assay
Myeloperoxidase (MPO) content was determined in lung homogenates using a spectrophotometric reaction with o'dianisidine hydrochloride as a substrate. Briefly, 240 µl of substrate solution (50 mM phosphate, 0.5% hexadecyltrimethylammonium buffer containing 0.167 mg/ml of o'dianisidine hydrochloride), 10 µl of H 2 O 2 (0.0005%), and 10 µl of sample or standards (human MPO from Sigma tested at 0, 0.078, 0.156, 0.3125, 0.625, 1.25, 2.5, and 5 U/ml) were mixed. The addition of sample starts the reaction. Absorbance was read at 450 nm on a plate reader, and the results were expressed as units/mg of total protein.
Lung cytokine protein expression
For the determination of cytokine protein levels in the lung tissue, approximately 200 mg of lung tissue was homogenized in 2 ml of ice-cold saline using an Ultraturrax T25 homogenizer. The samples were then spun in a benchtop microcentrifuge at 13,000 × rpm for 10 min [MSE Micro Centaur, Jencons (Scientific) Ltd, Leighton Buzzard, Bedfordshire, UK]. The resulting supernatants were used for cytokine protein quantification.
Cytokine levels were determined by enzyme-linked-immuno-sorbent assay (ELISA) using commercially available kits according to manufacturer's instructions. TNF-α, IL-1β, IL-6, CINC-2, and CINC-3 were determined using a rat-specific sandwich immunoassay kit obtained from R&D Systems (R&D Systems, Inc., Minneapolis, MN). MCP-1 and CINC-1 concentrations were determined using a solid-phase sandwich ELISA kit from BioSource UK, Ltd. (UK) and Amersham (UK), respectively. The detection limit of these assays was determined to be in the range of 1 to 5 pg/ml. Optical densities were read on a microplate reader at 450 nm (Biotek Instruments, Winooski, VT). Cytokine levels were corrected for total protein content, which was measured using the Bradford assay.
NF-κB p65 DNA binding in lung tissue
NF-κB pathway activity was measured using a TransAM NF-κB p65 ELISA-based assay kit (Active Motif, Rixensart, Belgium). Briefly, lung tissue was homogenized in lysis buffer (20 mM Tris HCl, 100 mM NaCl, 1 mM EDTA, 0.1% Nonidet P40, 0.05% sodium deoxycholate, 0.025% SDS, and 0.1% Triton X-100) containing 5 mM dithiothreitol and complete EDTA-free protease inhibitors (1 tablet in 50 ml of buffer). Protein concentration was determined by Bradford assay, and 100 µg of protein from each sample was used in the assay. Samples (20 µl) were placed along with 70 µl of binding buffer on a 96-well plate to which oligonucleotide containing an NF-ĸB consensus binding site had been immobilized, for 1 h on a rocker. During this time, the activated NF-ĸB contained in the sample specifically binds to this nucleotide; then the plate was washed and by using a primary antibody (100 µl diluted 1:1000 in antibody binding buffer for 1 h) that is directed against the NF-κB p65 subunit the NF-κB complex bound to the oligonucleotide is detected. The plate was then washed again, and 100 µl of secondary antibody (diluted 1:1000 in antibody binding buffer) conjugated to horseradish peroxidase (HRP) was added for 1 h. The plate was washed again, and 100 µl of developing solution was added. The plate was incubated for 2-10 min away from direct light, 100 µl of stop solution was added, and the plate was read using the MCC/340 Multiskan plate-reader at 450 nm.
Lung cytokine gene expression
Gene expression in the lung tissue was determined using a method outlined in McCluskie et al. (31) . Briefly, total cellular RNA was isolated from rat lungs using Tri Reagent (Sigma). The purity and integrity of the RNA samples were assessed by A 260 /A 280 spectrophotometric measurements on the GeneQuant RNA/DNA quantifier (Amersham Pharmacia Biotech, UK). RNA samples (1 µg) were reverse-transcribed on a Perkin Elmer 480 thermal cycler (Boston, MA). Samples were then stored at -20°C until required for analysis. Transcriptional expression of target mRNA transcripts in cDNA samples was detected by polymerase chain reaction (PCR) amplification and quantified by 5′-nuclease assay using fluorescent labeled Taqman probes (TaqMan; Applied Biosystems, Foster City, CA) and analyzed using real-time quantitative PCR with the ABI PRISM 7700 Sequence Detection System (Perkin-Elmer, PE Applied Biosystems, Tokyo, Japan).
Oligonucleotide primers and TaqMan probes for target genes (MMP-9, TIMP-1, CINC-1, CINC-2, CINC-3, iNOS, COX-1, COX-2, IL-6, VCAM-1, E-Selectin, P-Selectin, L-Selectin, MCP-1, and A1) were designed from published GenBank databases of mRNA sequences, using the Primer Express version 1.0 software (Perkin-Elmer, PE Applied Biosystems), TNF-α and IL-1β were pre-determined assay reagents (PDARs) from Applied Biosystems. The primers for the target gene used for real-time PCR were located in two different exons of each gene to avoid amplification of any contaminating genomic DNA. The TaqMan probe had a fluorescent reporter dye (FAM) covalently linked to its 5′-end and a downstream quencher dye (TAMRA) linked to its 3′-end. Fluorescence quenching depends on the spatial proximity of the reporter and quencher dyes. Reactions were internally controlled with the 18 s rRNA internal control (Perkin-Elmer, PE Applied Biosystems). Amplification and detection of specific products were performed in an ABI PRISM 7000 sequence detection system (Perkin-Elmer, PE Applied Biosystems). Results were analyzed using the Sequence Detection Software (Perkin-Elmer, PE Applied Biosystems), and the relative amount of target gene transcript was normalized to the amount of 18 s internal control transcript in the same cDNA sample. The data were then compared with levels in the saline/vehicle control group and are presented as fold increase over this group.
PGE 2 determination
PGE 2 was measured by radioimmunoassay (RIA) using a commercially available antibody and [ 3 H]-PGE 2 as described previously (38) . Samples of lung tissue homogenate supernatants (50-100 µl) or standards (1-40 ng/ml), diluted or made up to 100 µl in 50 mM Tris buffer (42 mM Tris HCl, 8 mM Tris base, 0.05% gelatin; pH 7.4), were incubated overnight at 4°C with 100 µl anti-PGE 2 antibody and 100 µl [
3 H]-PGE 2 both made up in Tris buffer. Activated charcoal (20 g/l) and dextran T70 (4 g/l), made up in Tris buffer without gelatin, were added to each sample tube. The samples were then centrifuged for 30 min at 3700 rpm at 4°C to separate bound from unbound radioactivity. After centrifugation, the supernatant was decanted into β-vials, mixed with 4 ml liquid scintillant (Pico-Fluor 40), and counted for 1 min in a liquid scintillation analyzer (2200CA Tri-carb Liquid Scintillation Analyser, Canberra Packard). Results, expressed in counts per minute (cpm), were converted to ng/ml by interpolation from a standard curve constructed to known concentrations of PGE 2 .
Satellite study-effect of intraperitoneal resveratrol
In a smaller study, using the same protocol detailed above, the rats were given vehicle (2 ml/kg, i.p., 0.5% methylcellulose, and 0.2% tween80 in saline) or resveratrol (30 mg/kg) 1 h before and 1 and 3 h after saline or LPS exposure. Cellular inflammation was assessed as detailed above. In addition, the remaining lung tissue was insufflated (at a pressure of 20 mmHg) with 10% neutral buffered formalin. After overnight in the fixative, the lungs were cleaned and processed into paraffin blocks. Paraffin sections (3 µM) were cut and stained with Mayer's hematoxylin and eosin for assessment of cellular inflammation.
Data analysis
Values are expressed as mean ± SEM of n independent observations. Statistical analysis was made using ANOVA with a correction for multiple comparisons. A P value <0.05 was considered to be statistically significant.
RESULTS
Effect of resveratrol and budesonide on inflammatory cell recruitment into the lung
Exposure to aerosolized LPS caused a significant increase in lung tissue neutrophil number. Treatment with resveratrol caused a dose-related significant inhibition of the lung tissue neutrophilia, which was of a similar magnitude to that achieved with treatment with budesonide ( Fig. 1) . None of the other white cell types in the lung tissue studies were affected by resveratrol treatment (Vehicle/saline: 123±35 and 3726±256; Vehicle/LPS: 176±55 and 3031±290; resveratrol (30 mg/kg)/LPS: 193±49 and 2879±563 cell × 10 3 /mg of tissue for eosinophils and lymphomononuclear cells, respectively). The focus of this study was on the inflammation in the lung tissue as it enabled direct comparisons between the impact of resveratrol on cellular influx, modulation of the NF-κB pathway, and mediator gene and protein expression. However, in the lavage fluid LPS exposure caused an influx of neutrophils and eosinophils (from 63±20 to 966±75 and from 2.0±0.5 to 22±5 cells × 10 3 /ml, respectively). Resveratrol (30 mg/kg) caused an increase in basal and LPS exposed levels of neutrophils [333±39 (P<0.05) and 1647±247 (non-significant) cells × 10 3 /ml, respectively]. Resveratrol (30 mg/kg) did not significantly impact on basal or LPS exposed levels of eosinophils (5.6±1.4 and 5.7±3.7 cells × 10 3 /ml, respectively).
Effect of resveratrol and budesonide on NF-ĸB p65 DNA binding and iNOS gene expression in the lung tissue
The amount of transcription factor NF-ĸB p65 able to bind to DNA was measured in the lung tissue using a p65 assay kit. Following LPS challenge, levels of NF-ĸB p65 able to bind to DNA were significantly increased compared with control levels, indicating an increase activity of this transcription factor pathway. Resveratrol appeared to have no impact on the LPS-induced increase in NF-κB pathway activity at any dose used in this experiment, whereas budesonide caused a significant, dose-dependent reduction in NF-κB p65 levels ( Fig. 2A) . However, one caveat is that this assay detects activated NF-κB but does not preclude that NF-κB was already bound to DNA consensus sites at the time the lungs were processed.
Budesonide, but not resveratrol, also caused a significant reduction in iNOS gene expression in the lung tissue (Fig. 2B ). This result contributes additional evidence to suggest that resveratrol does not modulate the activation of NF-κB pathway in this model as iNOS gene expression is linked to the activity of this transcription factor (39) .
Effect of resveratrol and budesonide on inflammatory mediator gene expression in the lung tissue
Exposure to aerosolized LPS resulted in a significant increase in gene expression of a range of pro-inflammatory mediators in the lung tissue (Table 1) . Treatment with resveratrol did not impact on any of the LPS-induced increases in gene expression measured. The positive control, budesonide, however caused dose-related inhibition of all of the pro-inflammatory genes measured ( Table 1 ). The profile of inhibition of these genes by budesonide generally mirrored the inhibition of NF-κB activity, which could suggest a causative link. Exceptions to this were the effects of budesonide on levels of CINC gene expression, which appeared to be more resistant to the steroid.
Many of the pro-inflammatory genes outlined in the introduction, to be inhibited by resveratrol in vitro, are not impacted on in this in vivo model. In fact, it appears that resveratrol treatment had a pro-inflammatory effect as it increased gene expression of many of the inflammatory biomarkers in the non-LPS and LPS treated groups ( Table 1) .
Effect of resveratrol and budesonide on inflammatory mediator protein expression in the lung tissue LPS exposure caused a significant increase in pro-inflammatory mediators in the lung tissue ( Fig. 3 and Table 2 ). Although resveratrol did not have a general inhibitory effect on proinflammatory mediators, it did cause a dose-related inhibition of TNF-α, IL-1β, MPO, and CINC-1 levels in the lung tissue ( Fig. 3 and Table 2 ). The positive control, budesonide, caused similar dose-related inhibition of all of the pro-inflammatory proteins increased by LPS treatment ( Fig. 3 and Table 2 ).
Effect of resveratrol and budesonide on prostanoid levels
Although resveratrol did not impact on lung tissue COX1 or COX2 gene expression, it did reduce PGE 2 levels (Fig. 4) , which suggests that resveratrol impacts on the activity of one or more of the enzymes involved in prostanoid production or release. Interestingly, although budesonide reduced the LPS-induced increase in gene expression of the inducible isoform COX-2, treatment resulted in an increase in the constitutive isoform COX-1 (Fig. 4) . The combination of these two opposing effects resulted in a small, non-significant, increase in PGE 2 (Fig. 4) .
Satellite study-effect of intraperitoneal resveratrol
LPS exposure caused an increase in BAL and tissue white cell number (neutrophils: from 0.4±0.2 to 577±73 cells × 10 3 /ml and from 1848±267 to 5914±671 cells × 10 3 /mg of tissue, respectively, and eosinophils from 0.0±0.0 to 87±10 cells × 10 3 /ml and from 381±42 to 668±113 cells × 10 3 /mg of tissue, respectively). Resveratrol-inhibited LPS induced neutrophils in the lavage fluid (27% non-significant) and lung tissue (67%, P<0.05) without impacting on eosinophilia. Unlike after intratracheal dosing, resveratrol given intraperitoneally had no proinflammatory effect on basal levels of white cells. Histological assessment of the lung tissue confirmed the results seen with the tissue digest, with the levels of inflammatory cells in the parenchyma, and not the airway, being reduced by resveratrol (data not shown).
DISCUSSION
Drinking moderate amounts of red wine has been suggested to have beneficial health effects (40) . One of the constituents of red wine that has been proposed to contribute to these beneficial health effects is resveratrol (1) . Over the past decade a great deal of research has been performed on this naturally occurring compound. Many of the inflammatory mediators demonstrated to be reduced by resveratrol in vitro are known to be involved in a rodent model of LPS-induced airway inflammation. The aim of this study was to determine whether these anti-inflammatory effects translate in vivo and whether resveratrol has any impact on the cellular inflammation in this model. The results suggest that resveratrol does possess anti-inflammatory properties in this pre-clinical rodent model. Treatment with this compound caused a dose-related reduction in TNF-α, IL-1β, and CINC-1 protein levels, PGE 2 levels, neutrophilia, and MPO, a marker of neutrophil activation, in the airway tissue.
In this model, resveratrol inhibited LPS-induced increases in lung tissue TNF-α, IL-1β, and CINC-1 levels. This result is in agreement with published in vitro data where resveratrol has been shown to reduce levels of these inflammatory mediators (15, 41, 42) . Interestingly, Culpitt and colleagues (43) have demonstrated an effect of resveratrol on macrophages from patients with COPD. Isolated lung macrophages, either unstimulated or stimulated with either IL-1β or cigarette smoke media, had reduced levels of IL-8 and GM-CSF in the presence of resveratrol. It is of interest that glucocorticoids were virtually ineffective in cells from these diseased patients; this finding raises the possibility that resveratrol might be a useful anti-inflammatory treatment for COPD, which is essentially resistant to steroids.
It appears that in this model treatment with resveratrol impacts on prostanoid production in the lung; this result agrees with similar in vitro results described by Dallal and colleagues (44) . Although studies have been published showing resveratrol to inhibit COX-1 and COX-2 gene expression in vitro (18, 19) , the results of this experiment suggest that the reduction in PGE 2 levels was not due to an impact on gene expression of either of these enzymes involved in the production in prostanoids. It seems likely that resveratrol reduced prostanoid levels by impacting on the activity of one or more of the enzymes involved in the production of PGE 2 , indeed Subbaramaiah and colleagues (19) have shown COX-2 activity to be reduced by resveratrol. Similarly, reports suggest that resveratrol inhibits iNOS gene expression and nitric oxide (NO) production in vitro (14, 16, 17) . In this model resveratrol did not impact on iNOS gene expression in the lung tissue. However, an impact on enzyme activity or NO production cannot be ruled out.
How resveratrol inhibits the production of these mediators in this pre-clinical model is not known. It appears from the lack of effect of this compound on the LPS-induced activation of the NF-κB pathway and on increased gene expression that resveratrol does not impact on the activation of the NF-κB pathway, as suggested by recent in vitro publications (27) (28) (29) (30) , in this model. Resveratrol could be affecting post-transcriptional parameters, translation, posttranslation modification, or release of these mediators, a phenomenon suggested by Kawada et al. (45) . One caveat to this is the possibility that unlike budesonide, which is known to remain in the lungs after administration into the airways, resveratrol may be cleared relatively quickly. This could mean that the reduction in pro-inflammatory protein levels was due to an earlier inhibition of gene transcription, which was not apparent at the time of tissue sampling due to the clearance of the compound. However, that caveat aside, these results suggest that this naturally occurring molecule may possess anti-inflammatory properties via a novel mechanism. Elucidation of this mechanism of action may lead to potential new therapies for the treatment of chronic inflammation.
Although some of the inflammatory markers suggested to be sensitive to treatment with resveratrol in in vitro studies were reduced in this model, many others, including activation of the NF-κB pathway, appeared to be resveratrol-insensitive. The reason for this is not known but could be because in general the in vitro studies demonstrating resveratrol activity are performed in human monocellular assay systems rather than rodent. Therefore, it may be that the effects of resveratrol in human assays do not always translate across into a multi-cellular in vivo assay system, such as this, in the rat.
Treatment with resveratrol inhibited the LPS-induced increases in lung tissue neutrophilia to a similar magnitude to that achieved with the positive standard, budesonide. While the exact mechanism of action is not known, these reductions in inflammatory cell recruitment observed with resveratrol treatment, appear to be associated with a decrease in TNFα, IL-1β, and CINC-1 protein levels, which may suggest a causative link. Indeed, LPS-induced airway neutrophilia has been reported to involve TNFα (46), IL-1β (32), and CINC-1 (33). Another possible reason for the impact seen with resveratrol on lung tissue neutrophilia could be associated with the reduction in PGE 2 levels observed. Decreases in PGE 2 levels have been reported to result in a reduction in a cytokine involved in neutrophilia, G-CSF (47) . Similarly, bradykinin has been shown to increase the neutrophil chemoattractant, IL-8, generation in airway epithelial cells via COX-2-derived prostanoids (48). In an LPS-driven model of airway neutrophilia, indomethacin, an inhibitor of prostanoid production, has been shown to decrease cell number (49). However, contrary to this finding others have published data showing that prostanoids are not involved in LPS-induced airway neutrophilia (50), while others report an increase in airway neutrophilia with indomethacin treatment in a similar model (51). Therefore, it appears that the role of prostanoids in this model of airway neutrophilia is not clear and it is not known whether the reduction in PGE 2 levels observed is related to the suppression of neutrophilia by resveratrol.
The effect of resveratrol in this pre-clinical model could be due to a number of other reasons, including modulation of apoptosis (22, 23, 24) . Indeed, in a recent publication by Martin et al. (52) resveratrol was shown to increase neutrophil apoptosis in a rat model of colonic inflammation. In this study, apoptosis was not measured per se; however, A1 gene expression, an anti-apoptotic marker, was not effected by resveratrol. Another possible mechanism of action of resveratrol could be related to its reported activity as a mixed agonist/antagonist at the estrogen receptor (53), although the anti-inflammatory properties of this compound have been shown to be independent of this nuclear receptor (54).
Another possible reason for the apparent effect of resveratrol on LPS-induced lung tissue neutrophilia could be due to the pro-inflammatory effect of resveratrol in the airway lumen, i.e., giving the compound into the airways has caused the neutrophils to move out of the tissue into the lumen. Indeed, in addition to the increase in basal and LPS-increased lavage levels of neutrophils, many of the pro-inflammatory genes measured in this study were increased in the non-LPS exposed lungs. We believe that this is due to a local irritant effect of giving the compound into the airways and is not the reason for the anti-inflammatory effect of resveratrol because in the satellite study when compound was given systemically, resveratrol again reduced airway neutrophilia without causing any pro-inflammatory effects in the lumen.
The positive anti-inflammatory control, budesonide, used in this study inhibited a broad range of inflammatory mediators and cellular recruitment. Generally there was a good correlation between the level of inhibition of the amounts of NF-κB p65 able to bind to DNA, inflammatory biomarker gene and protein expression, and cellular recruitment at each dose. While it is not known whether glucocorticoids inhibit the NF-κB pathway directly, it seems likely that the reduction in mediators known to stimulate the NF-κB pathway, such as TNF-α, is associated with the reduction in amounts of NF-κB p65 measured here. One group of inflammatory biomarkers that appeared to be partially resistant to budesonide treatment is the CINC family. Much higher doses of budesonide were necessary to impact on the gene and protein expression of the CINC family of chemokines compared with the other biomarkers. In addition the magnitude of the inhibition was far less than that of the other mediators impacted on by budesonide. This apparent steroid insensitivity seen in this study concurs with reported data from other studies (55-58). The small impact of budesonide treatment on CINC expression seen in this study could be due to the possible reduction in activation (due to the impact of budesonide on mediators that activate these cells, such as TNF-α) of cells believed to be responsible for the production of these cytokines such as macrophages, mast cells and epithelial cells (56, 59, 60). Exposure to LPS caused an increase in COX-2 gene expression and a reduction in COX-1 gene expression, which is similar to the results reported by Liu et al. (61) . Treatment with budesonide inhibited the increase in COX-2 gene expression, which concurs with data published by Wu et al. (62) and Musferrer et al. (63) but not by Liu et al. (61) . Interestingly, treatment with budesonide increased the gene expression of the constitutive isoform of COX, COX-1. This result is similar to that in other studies in which steroid treatment increases the expression of this COX isoform (64, 65) but different to the data published by Liu and co-workers (61) . The reasons for these discrepancies with steroid treatment on COX gene expression in this study and throughout the literature are not clear. In this study the opposing effects on COX-1 and COX-2 gene expression resulted in a non-significant increase in PGE 2 levels.
Recently, there has been a great deal of interest in this naturally occurring compound. In these experiments, we have demonstrated efficacy by the intraperitoneal route thus bypassing any issues relating to the low oral bioavailability of resveratrol and demonstrating efficacy by the systemic as well as the topical route. It is still not known whether this compound is rapidly cleared from the lungs and thus whether it is necessary to repeat dose the compound multiple times to ensure optimal lung effects. However, one of the main conclusions of this study having profiled this compound and described its activities would be to suggest that an optimized lead compound with similar biology but improved potency and pharmacokinetic profile may be a useful therapeutic.
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